Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

It is widely believed that machine learning and data mining are right on the cusp of becoming among the most important breakthroughs that the healthcare industry has seen in years. While applications of these techniques have already occurred elsewhere in the pharma sector, wide-spread applications in pharmaceutical commercial analytics have come more recently. Pharma companies are now looking to ...

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipeline productivity, and sustain a ROI on R&D spending needed for long-term drug development and commercial success. This means companies must look beyond current applications of commercial analytics focused mainly on ...

The pharmaceutical industry is changing and manufacturers need to modify approaches and structures to survive in a competitive environment. The pace of change necessitates that Pharmaceutical companies undergo a transformation; with organizations expanding the capabilities of their commercial models through smarter experimentation, scalable measurement, faster learning, and dynamic decision ...